the New Biomarker of the Knee Osteoarthritis Knee Osteoarthritis Occurrence and Progression
1 other identifier
observational
460
0 countries
N/A
Brief Summary
It was previously proved an association of TGF-β1 and PDGF-BB with the pathogenesis of osteoarthritis (OA) by experiments of OA animal models. In this study, we aimed to determine whether serum concentrations of TGF-β1, PDGF-BB and CTX-1 were related to the knee OA. knee OA cases were collected from the first affiliated hospital of Shihezi university and healthy controls were recruited from the community. The severity of knee OA was defined as kellgren-lawrence (K-L) classification criteria.Serum levels of chemical biomarkers were compared between knee OA cases and controls or among K-L grade 2 to grade 4 groups. The serum concentrations of the TGF-β1, PDGF-BB and CTX-1 were determined by ELISA .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2012
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
January 6, 2017
CompletedFirst Posted
Study publicly available on registry
January 10, 2017
CompletedJanuary 10, 2017
January 1, 2017
2.6 years
January 6, 2017
January 9, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum levels of Transforming Growth Factor Beta1 (TGF-β1) and Platelet Derived Growth Factor BB (PDGF-BB) may be novel biomarkers in knee osteoarthritis
3 years
Study Arms (2)
knee OA
OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded:the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
Control
"no often have pain, aching or stiffness in your Left/right knee during last month","no Left/right knee trauma history","no histories of glucocorticoid and/or sterol hormones" normal knee X-ray images,
Interventions
Eligibility Criteria
210 patients diagnosed with knee OA in clinics were found in hospital patients . Healthy controls were recruited from community questionnaires in Shihezi city, Xinjiang province, China.
You may qualify if:
- OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons
You may not qualify if:
- Participants who met the following criteria were excluded:
- the knee OA concomitant with hip OA,
- suppurative and rheumatoid arthritis,
- gout patients,
- patients who underwent knee arthroscopy surgery within 6 months,
- bilateral or unilateral knee replacements,
- the knee joint trauma patients,
- histories of glucocorticoid and/or sterol hormones.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
January 6, 2017
First Posted
January 10, 2017
Study Start
June 1, 2012
Primary Completion
January 1, 2015
Study Completion
June 1, 2015
Last Updated
January 10, 2017
Record last verified: 2017-01